American Cancer Society: Cancer facts & figures 2020. Estimated number of new cancer cases and deaths by sex, US, 2020.[https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annualcancer-facts-and-figures/2020/estimated-number-of-new-cancer-cases-and-deaths-by-sex-2020.pdf].
Tamada S, Iguchi T, Kato M, Asakawa J, Kita K, Yasuda S, et al. Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer. Oncotarget. 2018;9(97):36966–74. https://doi.org/10.18632/oncotarget.26426.
Article
Google Scholar
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54. https://doi.org/10.1016/S0140-6736(10)61389-X.
Article
CAS
Google Scholar
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12. https://doi.org/10.1056/NEJMoa040720.
Article
CAS
Google Scholar
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22. https://doi.org/10.1056/NEJMoa1001294.
Article
CAS
Google Scholar
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97. https://doi.org/10.1056/NEJMoa1207506.
Article
CAS
Google Scholar
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. https://doi.org/10.1056/NEJMoa1014618.
Article
Google Scholar
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23. https://doi.org/10.1056/NEJMoa1213755.
Article
CAS
Google Scholar
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322.
Article
CAS
Google Scholar
Zheng H, Chen J, Qiu W, Lin S, Chen Y, Liang G, et al. Safety and efficacy of first-line treatments for chemotherapy-naive metastatic castration-resistant prostate Cancer: a systematic review and indirect comparison. Biomed Res Int. 2017;2017:3941217. https://doi.org/10.1155/2017/3941217.
Article
CAS
Google Scholar
Tran K, McCormack S. CADTH rapid response reports. In: Androgen receptor targeted agents for castration resistant prostate Cancer: a review of clinical effectiveness and cost-effectiveness. Edn. Ottawa: Canadian Agency for Drugs and Technologies in Health. Copyright © 2019 Canadian Agency for Drugs and Technologies in Health; 2019.
Google Scholar
Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer. 2014;120(7):968–75. https://doi.org/10.1002/cncr.28518.
Article
CAS
Google Scholar
Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer. 2014;50(1):78–84. https://doi.org/10.1016/j.ejca.2013.08.020.
Article
CAS
Google Scholar
Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24(7):1807–12. https://doi.org/10.1093/annonc/mdt136.
Article
CAS
Google Scholar
Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802–7. https://doi.org/10.1093/annonc/mdt138.
Article
CAS
Google Scholar
Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol. 2014;65(1):30–6. https://doi.org/10.1016/j.eururo.2013.06.042.
Article
CAS
Google Scholar
Thomsen FB, Roder MA, Rathenborg P, Brasso K, Borre M, Iversen P. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol. 2014;48(3):268–75. https://doi.org/10.3109/21681805.2013.860189.
Article
CAS
Google Scholar
van Soest RJ, Nieuweboer AJ, de Morree ES, Chitu D, Bergman AM, Goey SH, et al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2015;51(17):2562–9. https://doi.org/10.1016/j.ejca.2015.07.037.
Article
CAS
Google Scholar
de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med. 2019;381(26):2506–18. https://doi.org/10.1056/NEJMoa1911206.
Article
Google Scholar
Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, et al. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials. Eur J Cancer. 2016;61:111–21. https://doi.org/10.1016/j.ejca.2016.04.002.
Article
CAS
Google Scholar
Satoh T, Ledesma D, Yoshihara N. The economic burden of metastatic castration resistant prostate Cancer and skeletal related events in Japanese University hospitals. Asian Pac J Cancer Prev. 2018;19(1):21–6. https://doi.org/10.22034/APJCP.2018.19.1.21.
Article
Google Scholar
McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C, et al. The clinical and economic impacts of skeletal-related events among Medicare enrollees with prostate Cancer metastatic to bone. Oncologist. 2016;21(3):320–6. https://doi.org/10.1634/theoncologist.2015-0327.
Article
Google Scholar
Grochtdreis T, Konig HH, Dobruschkin A, von Amsberg G, Dams J. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: a systematic review. PLoS One. 2018;13(12):e0208063. https://doi.org/10.1371/journal.pone.0208063.
Article
Google Scholar
Siddiqui M, Rajkumar SV. The high cost of cancer drugs and what we can do about it. Mayo Clin Proc. 2012;87(10):935–43. https://doi.org/10.1016/j.mayocp.2012.07.007.
Article
Google Scholar
Fizazi K, Kramer G, Eymard JC, Sternberg CN, de Bono J, Castellano D, et al. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Lancet Oncol. 2020;21(11):1513–25. https://doi.org/10.1016/S1470-2045(20)30449-6.
Article
CAS
Google Scholar
Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics. 2007;25(1):3–6. https://doi.org/10.2165/00019053-200725010-00002.
Article
Google Scholar
Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, et al. New therapeutic options in metastatic castration-resistant prostate cancer: can cost-effectiveness analysis help in treatment decisions? J Oncol Pharm Pract. 2014;20(6):417–25. https://doi.org/10.1177/1078155213509505.
Article
Google Scholar
Bilir SP, Ma Q, Zhao Z, Wehler E, Munakata J, Barber B. Economic burden of toxicities associated with treating metastatic melanoma in the United States. Am Health Drug Benefits. 2016;9(4):203–13.
Google Scholar
Bui CN, O'Day K, Flanders S, Oestreicher N, Francis P, Posta L, et al. Budget impact of Enzalutamide for chemotherapy-naive metastatic castration-resistant prostate Cancer. J Manag Care Spec Pharm. 2016;22(2):163–70. https://doi.org/10.18553/jmcp.2016.22.2.163.
Article
Google Scholar
Carter JA, Ji X, Botteman MF. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):483–96. https://doi.org/10.1586/14737167.2013.820959.
Article
Google Scholar
Roy A, Kish JK, Bloudek L, Siegel DS, Jagannath S, Globe D, et al. Estimating the costs of therapy in patients with relapsed and/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204–15.
Google Scholar
Sorensen S, Ellis L, Wu Y, Hutchins V, Linnehan JE, Senbetta M. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. J Manag Care Pharm. 2013;19(9):799–808. https://doi.org/10.18553/jmcp.2013.19.9.799.
Article
Google Scholar
CRG-EVERSANA Canada Inc. Data on file. Cost inflation tool. 2020.
Todenhofer T, Stenzl A, Hofbauer LC, Rachner TD. Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol. 2015;2015:838202. https://doi.org/10.1155/2015/838202.
Article
Google Scholar
Broder MS, Gutierrez B, Cherepanov D, Linhares Y. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer. 2015;23(1):237–47. https://doi.org/10.1007/s00520-014-2437-3.
Article
CAS
Google Scholar
DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007;15(7):869–76. https://doi.org/10.1007/s00520-006-0203-x.
Article
Google Scholar
Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O'Sullivan JM, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27(5):868–74. https://doi.org/10.1093/annonc/mdw065.
Article
CAS
Google Scholar
Flannery K, Drea E, Hudspeth L, Corman S, Gao X, Xue M, et al. Budgetary impact of Cabazitaxel use after Docetaxel treatment for metastatic castration-resistant prostate Cancer. J Manag Care Spec Pharm. 2017;23(4):416–26. https://doi.org/10.18553/jmcp.2017.23.4.416.
Article
Google Scholar
Academy of Managed Care Pharmacy. AMCP guide to pharmaceutical payment methods, 2013 update (version 3.0). Available at: http://www.amcp.org/pharmaceutical-payment-guide/. Accessed 18 Feb 2017.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–38. https://doi.org/10.1056/NEJMoa1315815.
Article
CAS
Google Scholar
Eisenberger M, Hardy-Bessard AC, Kim CS, Geczi L, Ford D, Mourey L, et al. Phase III study comparing a reduced dose of Cabazitaxel (20 mg/m (2)) and the currently approved dose (25 mg/m(2)) in Postdocetaxel patients with metastatic castration-resistant prostate Cancer-PROSELICA. J Clin Oncol. 2017;35(28):3198–206. https://doi.org/10.1200/JCO.2016.72.1076.
Article
CAS
Google Scholar
Centers for Medicare & Medicaid Services: Physician Fee Schedule Search.[https://www.cms.gov/apps/physician-fee-schedule/].
IBM Micromedex: RED BOOK.[https://www.micromedexsolutions.com/home/dispatch].